EXOZ · Exozymes Inc. · Executive Compensation
$5.52
-0.25 (-4.33%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's current operating cash burn, its existing working capital as of June 30, 2026, is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued, and management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.96M
Shares
9.28M
Volume · Oct 5
4451
Avg daily vol (3M)
7269
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher A. Marlett | Chairman of the Board | Appointed | 2025-02-21 |
| Mohammad Hayat | member of the Board of Directors | Resigned | 2025-02-21 |
| Edgardo Rayo | member of the Board | Appointed | 2025-02-21 |
| Mohammad Hayat | President and Chairman of the Board | Resigned | 2025-02-21 |